SEC Filing Analysis: GoodRx Holdings, Inc. (GDRX)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: A director was awarded 138,455 Restricted Stock Units (RSUs) as part of a standard compensation package, representing a moderate potential dilution to shareholders upon vesting.
• Market Impact: Neutral. This is a routine, non-cash compensation event and is not indicative of a change in the insider's market sentiment.

Company Information

Field	Value
Company	GoodRx Holdings, Inc.
Ticker Symbol	GDRX
CIK	0001809519
Industry	SERVICES-COMPUTER PROCESSING & DATA PREPARATION

Insider Information

Field	Value
Name	Bezdek Trevor
CIK	0001822104
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-02
Transaction Code	A (Award)
Security Type	Restricted Stock Units
Shares Involved	138,455
Price Per Share	$0.00
Total Value	$0
Shares Owned After	160,082 (Directly, Class A Common Stock)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	138,455
% of Shares Outstanding	0.14%
Post-Transaction Ownership	160,082 shares (0.16% of outstanding)
Materiality Assessment	Moderate

Impact Evaluation

• Market Cap Context: For a company with a $1.20 billion market cap, this non-cash grant is a routine part of executive and director compensation.
• Ownership Concentration: The insider's direct ownership remains modest at 0.16% of outstanding shares post-transaction, with additional indirect holdings in trusts.
• Dilution Impact: The grant of 138,455 RSUs represents a potential future dilution of 0.14% for existing shareholders. The vesting is scheduled over several years (2026-2028), spreading the impact over time.
• Transaction Significance: The significance is rated 'Medium' not due to value, but because the number of shares granted is a moderate percentage (0.14%) of total shares outstanding, falling within the 0.1% to 0.25% range for moderate significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a scheduled grant of equity as compensation. It is not a market purchase or sale and therefore does not signal a change in the insider's view of the company's valuation.

Volume & Sentiment

• Expected Volume Impact: None. As no shares were traded on the open market, this filing will not directly impact trading volume.
• Sentiment Indicator: Neutral. Equity grants are standard practice and are not typically viewed as bullish or bearish signals by the market.

Investment Insights

Positive Market Indicators

• The grant aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's future stock performance.

Risk Factors

• The issuance of new equity, even as compensation, contributes to shareholder dilution over the long term.

Key Takeaways

1. Routine Compensation: This is a standard equity award for a director, not an open-market transaction.
2. Moderate Dilution: The grant represents a 0.14% potential increase in shares outstanding once vested.
3. Future Vesting: The shares will not become available to the insider for several years, contingent on continued service, as specified in the footnotes (vesting begins in 2026).

Additional Context

Transaction Notes

• The filing reports two separate grants of RSUs on the same day, which have been aggregated for this analysis (33,530 and 104,925 units).
• Footnote F1: Details a vesting schedule where units vest in full on June 3, 2026.
• Footnote F5: Details a vesting schedule where one-third of the units vest on each anniversary of the grant date for three years, starting November 2, 2026.